Assertio Holdings Inc. (NASDAQ: ASRT) and Garda Therapeutics Inc. have mutually agreed to postpone the commencement of the previously announced tender offer to May 8, 2026, according to a company statement.

Under the amended merger agreement announced on May 4, 2026, Garda will acquire all outstanding shares of Assertio for $21.80 per share in cash, representing total consideration of $153.2 million. The Lake Forest, Illinois-based pharmaceutical company expects to file a Schedule 14D-9 in connection with the tender offer on May 8, 2026.

Assertio will also postpone the commencement of the previously announced tender offer for all outstanding Convertible Senior Notes until the same date.

The company focuses on marketing products primarily in the oncology market and describes itself as having comprehensive commercial capabilities for differentiated pharmaceutical products.

The information is based on a press release statement from Assertio Holdings Inc.